Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Anticonvulsant
JNJ-26489112
Другие языки:

    JNJ-26489112

    Подписчиков: 0, рейтинг: 0
    JNJ-26489112
    JNJ-26489112.svg
    Identifiers
    • (S)-N-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C9H11ClN2O4S
    Molar mass 278.71 g·mol−1
    3D model (JSmol)
    • NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2
    • InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1
    • Key:KXSAIQPPGSSNKX-ZETCQYMHSA-N

    JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.

    JNJ-26489112 was studied as a treatment for major depressive disorder. This clinical trial was terminated in 2013 due to a "sponsor portfolio decision", and no new development of JNJ-26489112 has been reported.

    Its mechanism of action is unknown.

    See also

    Further reading

    • Toxicological study of JNJ-26489112: Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, et al. (July 2014). "Implications of retinal effects observed in chronic toxicity studies on the clinical development of a CNS-active drug candidate". Regulatory Toxicology and Pharmacology. 69 (2): 187–200. doi:10.1016/j.yrtph.2014.03.005. PMID 24680767.

    Новое сообщение